pH protective Y1 receptor ligand functionalized antiphagocytosis BPLP-WPU micelles for enhanced tumor imaging and therapy with prolonged survival time
Source abstract
Abstract
Nanoparticle-based tumor therapies are extensively studied; however, few are capable of improving patient survival time due to premature drug leakage, off target effects, and poor tissue penetration. Previously, we successfully synthesized a novel family of Y1 receptor (Y1R) ligand modified, photoluminescent BPLP nanobubbles and nanoparticles for targeted breast cancer ultrasound imaging; however, increased accumulation could also be observed in the liver, kidney, and spleen, suggesting significant interaction of the particles with macrophages in vivo. Herein, for the first time, we imparted antiphagocytosis capability to Y1R ligand functionalized BPLP-WPU polymeric micelles through the incorporation of a CD47 human glycoprotein based self-peptide. Application of self-peptide modified, DOX loaded micelles in vivo resulted in a 100% survival rate and complete tumor necrosis over 100 days of treatment. In vivo imaging of SPION loaded, self-peptide modified micelles revealed effective targeting to the tumor site while analysis of iron content demonstrated reduced particle accumulation in the liver and kidney, demonstrating reduced macrophage interaction, as well as a 2-fold increase of particles in the tumor. As these results demonstrate, Y1R ligand, self-peptide modified BPLP-WPU micelles are capable of target specific cancer treatment and imaging, making them ideal candidates to improve survival rate and tumor reduction clinically.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Breast cancer statistics, 2017, racial disparity in mortality by state
2. Global cancer statistics, 2012
3. Silk fibroin nanoparticle as a novel drug delivery system10.1016/j.jconrel.2015.03.020 ↗
4. Fabrication and characterization of a new MRI contrast agent based on a magnetic dextran-spermine nanoparticle system10.1007/s13726-012-0027-0 ↗
5. Novel peptide conjugates for tumor-specific chemotherapy10.1021/jm001065f ↗
6. Effect of nanoparticles on the cell life cycle10.1021/cr1003166 ↗
7. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
8. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology10.1016/j.addr.2013.11.009 ↗
9. Innovative technology of engineering magnetic DNA nanoparticles for gene therapy10.1504/IJNT.2011.041441 ↗
10. In vitro assessment of magnetic dextran-spermine nanoparticles for capecitabine delivery to cancerous cells
11. Polymeric nanoparticles for therapy and imaging10.1002/pat.3381 ↗
12. ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy10.1002/adma.201700141 ↗
13. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration10.1021/nn504210g ↗
14. Development of intrinsically photoluminescent and photostable polylactones10.1002/adma.201306070 ↗
15. Fluorescence imaging enabled poly(lactide-co-glycolide)10.1016/j.actbio.2015.10.010 ↗
16. NPY receptors in human cancer: a review of current knowledge10.1016/j.peptides.2006.08.037 ↗
17. Y-1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets
18. Neuropeptide Y receptors: a promising target for cancer imaging and therapy10.1093/rb/rbv013 ↗
19. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application10.1002/anie.200905008 ↗
20. Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET10.1021/mp500601z ↗
21. [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging10.1016/j.bmcl.2009.12.068 ↗
22. Neuropeptide Y Y-1 receptors meditate targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy10.1021/acsami.5b00270 ↗
23. Neuropeptide Y Y1 receptor-mediated biodegradable photoluminescent nanobubbles as ultrasound contrast agents for targeted breast cancer imaging10.1016/j.biomaterials.2016.11.028 ↗
24. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
25. Getting drugs across biological barriers10.1002/adma.201606596 ↗
26. The cell biology of phagocytosis10.1146/annurev-pathol-011811-132445 ↗
27. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
28. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle10.1126/scitranslmed.aac6522 ↗
29. Peptide nanoparticle with pH-sensing cargo solubility enhances cancer drug efficiency10.1016/j.nantod.2017.02.008 ↗
30. Cancer nanomedicine: is targeting our target?10.1038/natrevmats.2016.69 ↗
31. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles10.1126/science.1229568 ↗
32. Role of CD47 as a marker of self on red blood cells10.1126/science.288.5473.2051 ↗
33. Integrin-associated protein (CD47) and its ligands10.1016/S0962-8924(00)01906-1 ↗
34. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis10.1038/nrc1713 ↗
35. Targeting the molecular effects of a hypoxic tumor microenvironment10.2741/2372 ↗
36. Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis
37. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications10.1002/adma.201300299 ↗
38. Tumor cell metabolism an integral view10.4161/cbt.12.11.18140 ↗
39. pH-sensitive nano-systems for drug delivery in cancer therapy10.1016/j.biotechadv.2013.11.009 ↗
40. pH-responsive aerobic nanoparticles for effective photodynamic therapy10.7150/thno.19546 ↗
41. Current multistage drug delivery systems based on the tumor microenvironment10.7150/thno.16684 ↗
42. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel10.1016/j.biomaterials.2011.11.078 ↗
43. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs10.1016/S0005-2736(01)00441-2 ↗
44. pH-sensitive nanoparticles of poly(L-histidine)-poly(lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery10.1016/j.actbio.2014.09.014 ↗
45. pH-sensitive peptide hydrogel for glucose-responsive insulin delivery10.1016/j.actbio.2017.01.016 ↗
46. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery10.1016/j.biomaterials.2012.08.072 ↗
47. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity10.1016/j.jconrel.2015.12.006 ↗
48. Novel analogues of neuropeptide Y with a preference for the Y1-receptor10.1046/j.1432-1327.2001.02161.x ↗
49. Exploring a new SPION-based MRI contrast agent with excellent water-dispersibility, high specificity to cancer cells and strong MR imaging efficacy10.1016/j.colsurfb.2014.11.045 ↗
50. Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery10.1021/ja311180x ↗
51. Polymer micelle-based combination therapy of paclitaxel and resveratrol with enhanced and selective antitumor activity10.1039/C4RA09761K ↗
52. A near infrared light triggered hydrogenated black TiO2 for cancer photothermal therapy10.1002/adhm.201500273 ↗
53. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles10.2147/IJN.S36111 ↗
54. Cellular uptake of nanoparticles: journey inside the cell10.1039/C6CS00636A ↗
55. Black TiO2 based core-shell nanocomposites as doxorubicin carriers for thermal imaging guided synergistic therapy of breast cancer10.1039/C7NR04039C ↗
56. 808 nm-excited upconversion nanoprobes with low heating effect for targeted magnetic resonance imaging and high-efficacy photodynamic therapy in HER2-overexpressed breast cancer10.1016/j.biomaterials.2016.06.037 ↗
57. Biocompatible poly(2-hydroxyethyl methacrylate)-b-poly(L-histidine) hybrid materials for pH-sensitive intracellular anticancer drug delivery10.1002/adfm.201102756 ↗
58. pH-responsive peptide mimic shell cross-linked magnetic nanocarriers for combination therapy10.1002/adfm.201201140 ↗
59. Small-angle scattering studies of biological macromolecules in solution10.1088/0034-4885/66/10/R05 ↗
60. Form follows function: nanoparticle shape and its implications for nanomedicine10.1021/acs.chemrev.7b00194 ↗
61. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo10.1073/pnas.0702439104 ↗
62. Tumor microenvironment-triggered aggregation of antiphagocytosis 99mTc-labeled Fe3O4 nanoprobes for enhanced tumor imaging in vivo10.1002/adma.201701095 ↗
63. A pH-responsive yolk-like nanoplatform for tumor targeted dual-mode magnetic resonance imaging and chemotherapy10.1021/acsnano.7b02675 ↗